



## PRESS RELEASE

23 January 2026 11:50:00 CET

### AcouSort initiates new collaboration with global manufacturer

**AcouSort AB today announced it has initiated a feasibility project with a large international manufacturing company aiming at investigating the applicability of AcouSort's technology for removing particles in different steps of production workflows.**

"This is a very exciting project that demonstrates the versatility of AcouSort's technology, and we are very excited over the opportunity this new collaboration brings," said AcouSort's CEO Dr. Torsten Freltoft.

The customer is a large international company active within manufacturing. The aim of the project is to see if AcouSort's technology could be used to improve the quality of the company's production liquids thus improving the production yield.

The first feasibility project includes a smaller pre-study as well as delivery of two prototype devices that can be evaluated at the customer's facilities. AcouSort's part of the project was concluded just before New Year. Evaluation of the prototype units at the customer site is planned for Q1 2026. If the results are positive, the project has the potential to turn into a more long-term collaboration aiming at developing an inline solution that can be implemented as part of their production process.

Revenues generated from this initial feasibility project is expected to be USD 40,000.

#### **FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:**

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: [torsten.freltoft@acousort.com](mailto:torsten.freltoft@acousort.com)

#### **ABOUT ACOUSORT**

*AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Tapper Partners AB.*